Overcoming five main challenges to targeting hematologic malignancies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 42247978.
- Also identified by DOI 10.1016/j.jcyt.2026.102776.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The development and application of chimeric antigen receptor (CAR) T-cell therapies have changed the treatment landscape of hematologic malignancies. While there are currently FDA approved products for their use in relapsed or refractory B-cell and plasma cell malignancies, ongoing research efforts strive to target difficult to treat antigens and diseases. In this review, we discuss five main challenges involving CAR-T cell products in hematologic malignancies. Additionally, we propose mechanisms to overcome these challenges that monitor adverse effects, improve universal access, enhance manufacturing platforms, and advance commercialization with the goal of optimal patient care.